Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Minghui Pharmaceutical Limited

Guoqing Cao

Lianshan Zhang

Changyong Yang

Weikang Tao

Piaoyang Sun

Xiangdong Qu

Qiyue Hu

Lei Zhang

Xin Ye

Jijun Yuan

Xing Sun

Yong Guo

Li Yang

Dongbing Cui

Jiahua Jiang

Junqing Pan

Yanzhi Sun

Yinjian Niu

Tixian Chen

Shaoyu Xu

Yongquan Ma

Xiaoxiang Cai

Longrui Zhou

Jufang Lin

Houcong Jin

Mingming Zhou

Xiaowei Liu

Shuang Song

Xinxin Yang

Qing Dong

Jiong Lan

Jianbiao Peng

Yuanshan Yao

Ao Qiong Li

Jiajian Liu

Fangfang Jin

Zhaoyin Wang

Bonian Liu

Xiaotao Li

Xiaoxing Huang

Xueming Qian

Fei Teng

Bing Yao

Zhibin Xu

Chunyan Gu

Ke Ma

Chunzhou Han

Jianjun Zou

Shude Yan

Kan Chen

Xuan Zhang

Ao Li

Jianglin Wang

Yunfei Yang

Xin Wu

Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating cancers.

Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers

The present invention relates to a novel molecule with protein tyrosine kinase inhibitory activity, and the synthesis and usage thereof. Specifically, the present invention relates to compound by formula A, pharmaceutically acceptable salts, hydrates or solvates thereof, and the synthesis and usage thereof.

Cyclic molecules as Bruton's tyrosine kinase inhibitor

The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.

PD-L1 antibody, antigen-binding fragment thereof and medical application thereof

Provided are an anti-CD40 antibody, an antigen binding fragment thereof, and a medical use thereof. Also provided are a chimeric antibody and a humanized antibody including a CDR region of the anti-CD40 antibody, a pharmaceutical composition including the human anti-CD40 antibody and the antigen binding fragment thereof, and an application thereof as an anti-cancer drug. In particular, provided are a humanized anti-CD40 antibody, and an application thereof in preparation of a drug to treat a CD40-mediated disease or disorder.

Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof

Disclosed is the use of a KOR agonist in combination with a MOR agonist in preparing a drug for treating pain. The KOR agonist is selected from a compound as shown in the general formula (I), and the MOR agonist is selected from a compound as shown in the general formula (II), wherein the definitions of each substituent in the general formula (I) and (II) are the same as defined in the description. 

Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain

The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.

PD-1 antibody, antigen-binding fragment thereof, and medical application thereof

This application describes a use of an EZH2 inhibitor combined with a BTK inhibitor in preparing a drug for treating a tumor is described.

Use of EZH2 inhibitor combined with BTK inhibitor in preparing drug for treating tumor

A combination of a VEGFR inhibitor and a PARP inhibitor is described. In particular, this combination can be used in the preparation of a medicament for treating gastric cancer.

Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer

Provided is an IL-15 heterodimeric protein, such as an IL-15/IL-15R&#x3b1; heterodimeric protein. The IL-15 heterodimeric protein contains protein (I) and protein (II). Protein (I) is recombinantly produced by combining IL-15 or a variant thereof with a first Fc variant, and protein (II) is a second Fc variant, or recombinantly produced by combining IL-15R&#x3b1; or a variant thereof with a second Fc variant. The first Fc variant and the second Fc variant are preferably linked via a 'Knob-into-Hole' mode. Also provided are methods of using the IL-15 heterodimeric proteins to modulate an immune response. The provided IL-15 heterodimeric proteins have significant anti-tumor activity, better biological activity and prolonged in vivo half-life compared to the IL-15 molecule alone.

IL-15 heterodimeric protein and uses thereof

Provided is an antibody capable of specially recognizing IL-17A and binding to IL-17A. The antibody can be used for treating inflammation and autoimmune diseases caused by elevated expression of interleukin-17A, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis.

IL-17A binding agent and uses thereof

Cycloalkyl acid derivatives, a preparation method thereof, and a pharmaceutical application thereof are described. In particular, a cycloalkyl acid derivative represented by general formula (I) and a medical salt thereof, a preparation method thereof, and an application of the cycloalkyl acid derivative and the medical salt thereof as URAT1 inhibitors, and particularly as therapeutic agents for diseases related to an abnormal uric acid level are described, wherein definitions of substituent groups in general formula (I) are the same as the definitions in the specification. 

Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof

Growing community of inventors

Jiangsu, China

Guoqing Cao